Abstract: A plasma processing apparatus includes a balun having a first unbalanced terminal, a second unbalanced terminal, a first balanced terminal, and a second balanced terminal, a grounded vacuum container, a first electrode electrically connected to the first balanced terminal, a second electrode electrically connected to the second balanced terminal, an impedance matching circuit, a first power supply connected to the balun via the impedance matching circuit, and configured to supply a high frequency to the first electrode via the impedance matching circuit and the balun, a low-pass filter, and a second power supply configured to supply a voltage to the first electrode via the low-pass filter.

Abstract: The present invention relates to a method for inducing production of vascular endothelial growth factor (VEGF). The method includes administering, to an individual, a composition including adeno-associated virus (AAV) carrying a hPGIS gene coding for human prostacyclin synthase (hPGIS) which synthesizes prostaglandin I2 (PGI2).

Abstract: Drug compositions of angiogenesis therapy contain gene coding for human prostacyclin synthase (hPGIS) synthesizing prostaglandin I2 with activities of vasodialation and/or anti-platelet aggregation; drug compositions contain adeno-associated virus (AAV) inserted with gene for angiogenesis factors. The administration of the drug compositions into the aimed treatment region results in transfer of AAV type 1-hPGIS to skeletal muscles and induces a notable expression of human PGIS gene in skeletal muscles. The PGI2 is produced by mediation of the gene expression in the muscle cells, secreted, induces vessel-protective, neovascularization and anti-platelet aggregation actions, which lead to an improvement in vascular ischemia.

Abstract: The present invention relates to a method for inducing production of vascular endothelial growth factor (VEGF). The method includes administering, to an individual, a composition including adeno-associated virus (AAV) carrying a hPGIS gene coding for human prostacyclin synthase (hPGIS) which synthesizes prostaglandin I2 (PGI2).

Abstract: Drug compositions of angiogenesis therapy contain gene coding for human prostacyclin synthase (hPGIS) synthesizing prostaglandin I2 with activities of vasodialation and/or anti-platelet aggregation; drug compositions contain adeno-associated virus (AAV) inserted with gene for angiogenesis factors. The administration of the drug compositions into the aimed treatment region results in transfer of AAV type 1-hPGIS to skeletal muscles and induces a notable expression of human PGIS gene in skeletal muscles. The PGI2 is produced by mediation of the gene expression in the muscle cells, secreted, induces vessel-protective, neovascularization and anti-platelet aggregation actions, which lead to an improvement in vascular ischemia.

Abstract: The present invention relates to a method for inducing production of vascular endothelial growth factor (VEGF).

Abstract: The present invention relates to: drug compositions of angiogenesis therapy that contains gene coding for human prostacyclin synthase (hPGIS) synthesizing prostaglandin I2 with activities of vasodialation and/or anti-platelet aggregation; drug compositions contain adeno-associated virus (AAV) inserted with gene for angiogenesis factors. The administration of the drug compositions into the aimed treatment region results in transfer of AAV type 1-hPGIS to skeletal muscles and induces a notable expression of human PGIS gene in skeletal muscles. The PGI2 is produced by mediation of the gene expression in the muscle cells, secreted, induces vessel-protective, neovascularization and anti-platelet aggregation actions, which lead to an improvement in vascular ischemia.

Abstract: A user interface device and a PDA include: a transparent panel unit possessing plural layers, each provided with plural transparent deformation sections deformable to a specified shape by injection or discharge of fluid; a fluid channel unit possessing, in common or separately, two transparent fluid channels to inject and to discharge fluid to and from the deformation sections; a fluid pump unit to discharge or suck fluid to and from the fluid channel unit; a display panel unit provided with the transparent panel unit over an upper surface of the display panel unit and possessing a screen surface to display an image; and a controller to control injection and discharge of the fluid to and from the deformation sections of the transparent panel unit, corresponding to an image to be displayed on the screen of the display panel unit. Information can be conveyed tactilely and visually to a user.

Abstract: The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets 1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an an

Abstract: The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets 1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an an

Abstract: A user interface device and a PDA include: a transparent panel unit possessing plural layers, each provided with plural transparent deformation sections deformable to a specified shape by injection or discharge of fluid; a fluid channel unit possessing, in common or separately, two transparent fluid channels to inject and to discharge fluid to and from the deformation sections; a fluid pump unit to discharge or suck fluid to and from the fluid channel unit; a display panel unit provided with the transparent panel unit over an upper surface of the display panel unit and possessing a screen surface to display an image; and a controller to control injection and discharge of the fluid to and from the deformation sections of the transparent panel unit, corresponding to an image to be displayed on the screen of the display panel unit. Information can be conveyed tactilely and visually to a user.

Abstract: The present invention relates to: pharmaceutical compositions for inducing apoptosis in cells, the pharmaceutical compositions comprising a prostacyclin synthase gene as an active ingredient; pharmaceutical compositions for gene therapy of cancer, the pharmaceutical compositions comprising the above pharmaceutical compositions for inducing apoptosis as an active ingredient; and a screening method for an agent that induces apoptosis in a cell, the method comprising determining the activation of peroxisome proliferator-activated receptor (PPAR)-? in the presence of a test substance. The pharmaceutical composition of the present invention for inducing apoptosis enables treatment of diseases on which induction of apoptosis has a therapeutic effect. In addition, the pharmaceutical composition of the present invention for gene therapy can lead cancer cells to cell death. Furthermore, the screening method of the present invention can be used conveniently to screen for agents capable of inducing apoptosis.

Abstract: The present invention clarifies the primary structure of human-originated PGIS and the nucleotide sequence encoding same. The PGIS and its DNA are useful as reagents for the development of therapeutic agents for the cardiovascular diseases induced by the production imbalance between PGI2 and TXA2, and as diagnostics for determining the in vivo tissue expression level and distribution of PGIS or mRNA thereof. Moreover, they can be used as therapeutic agents for cardiovascular diseases, which introduce PGIS and the like into human or other animals in a lesion-specific manner. The production method of the present invention is useful for the easy and efficient mass production of the human-originated PGIS. The antibody of the present invention is useful for the purification of the human-originated PGIS and immunohistochemical analysis of the cause of a disease.

Abstract: According to the present invention, the gene for IL-13, an anti-inflammatory cytokine, was shown to be a target of prostacyclin (PGI2)-activated Peroxisome proliferator-activated receptor (PPAR) ?. Furthermore, the PGI2-PPAR? signaling pathway was revealed to regulate the expression of IL-13 gene in human vascular endothelial cells, and controls inflammatory responses induced by proinflammatory cytokines through the production of IL-13 in an autocrine or paracrine manner. Thus, the present invention provides a method for treating or preventing inflammatory disorders, which comprises administering a therapeutically effective amount of PPAR? agonist into a subject. Furthermore, the present invention provides a method for treating or preventing inflammatory disorders, which comprises administering a prostacyclin synthase gene or a protein encoded by the gene into a subject.

Abstract: The present invention clarifies the primary structure of human-originated PGIS and the nucleotide sequence encoding same. The PGIS and its DNA are useful as reagents for the development of therapeutic agents for the cardiovascular diseases induced by the production imbalance between PGI2 and TXA2, and as diagnostics for determining the in vivo tissue expression level and distribution of PGIS or mRNA thereof. Moreover, they can be used as therapeutic agents for cardiovascular diseases, which introduce PGIS and the like into human or other animals in a lesion-specific manner. The production method of the present invention is useful for the easy and efficient mass production of the human-originated PGIS. The antibody of the present invention is useful for the purification of the human-originated PGIS and immunohistochemical analysis of the cause of a disease.

Abstract: A DNA-comprising a DNA having a nucleotide sequence encoding the amino acid sequence of human-originated prostacyclin synthase (PGIS) substantially depicted in Sequence No. 12, a vector comprising said DNA, a host cell transformed with said vector and a method for preparing human-originated PGIS comprising culturing said host cell in a medium. A polypeptide having the amino acid sequence of human-originated PGIS substantially depicted in Sequence No. 12 and an antibody having a reactivity with said human-originated PGIS. A pharmaceutical composition comprising said DNA or a vector comprising said DNA. A method for promoting the production of PGI2 and a method for treating the diseases induced by a low production of PGI2, comprising introducing said DNA or a vector comprising said DNA into human or other animals.

Abstract: The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets 1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an an

Abstract: An air conditioner outlet vent device includes a housing having a blow-out hole at its front end; a plurality of fins which are supported in parallel in the blow-out hole and each of which is capable of pivoting about its axis, the axes being parallel to one another; a common link which extends in an arrangement direction of the fins and to which the fins are pivotably connected at their rear ends; a pair of outer fins disposed at opposite ends in the arrangement direction of the fins, the outer fins each integrally including a shield plate which protrudes toward one of a pair of sidewalls of the housing so as to define opposite ends of the blow-out hole. In this device, a distance between a support point of each of the outer fins in the housing and a linkage point of the outer fin to the link is set larger than a distance between a support point of each of the fins other than the outer fins and its linkage point to the link.

Abstract: An air conditioner outlet vent device includes a housing having a blow-out hole at its front end; a plurality of fins which are supported in parallel in the blow-out hole and each of which is capable of pivoting about its axis, the axes being parallel to one another; a common link which extends in an arrangement direction of the fins and to which the fins are pivotably connected at their rear ends; a pair of outer fins disposed at opposite ends in the arrangement direction of the fins, the outer fins each integrally including a shield plate which protrudes toward one of a pair of sidewalls of the housing so as to define opposite ends of the blow-out hole. In this device, a distance between a support point of each of the outer fins in the housing and a linkage point of the outer fin to the link is set larger than a distance between a support point of each of the fins other than the outer fins and its linkage point to the link.

Abstract: The present invention clarifies the primary structure of human-originated PGIS and the nucleotide sequence encoding same. The PGIS and its DNA are useful as reagents for the development of therapeutic agents for the cardiovascular diseases induced by the production imbalance between PGI.sub.2 and TXA.sub.2, and as diagnostics for determining the in vivo tissue expression level and distribution of PGIS or mRNA thereof. Moreover, they can be used as therapeutic agents for cardiovascular diseases, which introduce PGIS and the like into human or other animals in a lesion-specific manner. The production method of the present invention is useful for the easy and efficient mass production of the human-originated PGIS. The antibody of the present invention is useful for the purification of the human-originated PGIS and immunohistochemical analysis of the cause of a disease.